Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.63 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.63 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.63 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.63 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.63 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.63 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.63 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.63 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.63 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182154 | 0.88 | CYP1A1 (0.61) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL2587121 | 0.85 | SELL (0.62) | FFAR1CTSASELLSELPALDH1A1 | |
| SCHEMBL4207967 | 0.83 | PTGS1 (0.59) | CYP1A2PTGS1AKR1C3AKR1C2FFAR1 | |
| SCHEMBL20519924 | 0.81 | GAA (0.62) | PTGS1AKR1C3AKR1C2SELLSELP | |
| SCHEMBL4201864 | 0.81 | PTGS1 (0.58) | PTGS1AKR1C3AKR1C2FFAR1ALDH1A1 | |
| SCHEMBL9225987 | 0.80 | CYP1A1 (0.65) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL29824310 | 0.79 | PTGS1 (0.67) | CYP1A2PTGS1AKR1C3AKR1C2HSD17B10 | |
| SCHEMBL229067 | 0.79 | PTGS1 (0.67) | CYP1A2PTGS1AKR1C3AKR1C2HSD17B10 | |
| SCHEMBL12477046 | 0.79 | GAA (0.49) | FFAR1PTPN11THRATHRBSELL | |
| SCHEMBL4171948 | 0.79 | CYP2C8 (0.69) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1948146-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | Revotar Biopharmaceuticals AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | SELP, SELE, SELL | CYP1A1 1575/4885CYP1A2 1147/4885CYP2E1 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.